Life science company ValiRx Plc (AIM: VAL) announced on Monday that its wholly owned subsidiary, Inaphaea BioLabs Limited, has shipped its first batch of Patient Derived Cells (PDCs) as part of its new Assay Ready Reagents (ARR) product line.

These reagents, which are ready for immediate use in assays without the need for in-house cultivation, represent a potential new revenue stream for Inaphaea. While the order value is not significant, it validates the product offering and underscores its commercial potential.

ValiRx continues to focus on early-stage cancer therapeutics and women's health, facilitating the translation of innovative scientific discoveries into impactful medicines.

The company uses its expertise to guide novel drug candidates from pre-clinical studies to investor-ready assets, partnering with collaborators for further clinical development and commercialisation.